Federal Register - February 4, 2021
Versione di testo Cosa è?Dateas è un sito indipendente non affiliato a entità governative. La fonte dei documenti PDF che pubblichiamo qui è l'entità governativa indicata in ciascuno di essi. Le versioni in testo sono trascrizioni che realizziamo per facilitare l'accesso e la ricerca di informazioni, ma possono contenere errori o non essere complete.
Source: Federal Register
Federal Register / Vol. 86, No. 22 / Thursday, February 4, 2021 / Notices Fishers Lane, Room 3G31B, Rockville, MD
20852, 240 6695060, james.snyder@
nih.gov.
Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
FR Doc. 202102274 Filed 2321; 8:45 am
Government-Owned Inventions;
Availability for Licensing
BILLING CODE 414001P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
FR Doc. 202102302 Filed 2321; 8:45 am
National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health National Center for Advancing Translational Sciences; Notice of Closed Meeting Pursuant to section 10d of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the provisions set forth in sections 552bc4 and 552bc6, Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Center for Advancing Translational Sciences Special Emphasis Panel; Rare Diseases.
Date: February 18, 2021.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Boulevard, Room 1076, Bethesda, MD 20892 Virtual Meeting.
Contact Person: Carol Lambert, Ph.D., Office of Scientific Review, National Center for Advancing Translational Sciences, National Institutes of Health, 6701
Democracy Boulevard, Room 1076, Bethesda, MD 20892, 3014350814, lambert@
mail.nih.gov.
Catalogue of Federal Domestic Assistance Program Nos. 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.350, BCooperative Agreements; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS
VerDate Sep<11>2014
17:13 Feb 03, 2021
Jkt 253001
National Institutes of Health
AGENCY:
Dated: January 27, 2021.
Tyeshia M. Roberson, Program Analyst, Office of Federal Advisory Committee Policy.
BILLING CODE 414001P
jbell on DSKJLSW7X2PROD with NOTICES
Dated: January 22, 2021.
David W. Freeman, Program Analyst, Office of Federal Advisory Committee Policy.
Pursuant to section 10d of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the provisions set forth in sections 552bc4 and 552bc6, Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Resource Related Research Projects R24 Clinical Trial Not Allowed.
Date: February 23, 2021.
Time: 10:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G20, Rockville, MD 20892 Virtual Meeting.
Contact Person: Zhuqing Charlie Li, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G20, Rockville, MD 20852, 240 6695068, zhuqing.li@nih.gov.
Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS
Dated: January 26, 2021.
Tyeshia M. Roberson, Program Analyst, Office of Federal Advisory Committee Policy.
FR Doc. 202102275 Filed 2321; 8:45 am
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is owned by an agency of the U.S.
Government and is available for licensing as a biological material to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
FOR FURTHER INFORMATION CONTACT:
Jeffrey Thruston at 3015945179 or jeffrey.thruston@nih.gov. Licensing information may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301496
2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention.
SUPPLEMENTARY INFORMATION:
Technology description follows:
SUMMARY:
National Institutes of Health
BILLING CODE 414001P
8213
A VSVEBOV-Based Vaccine Against COVID19
Description of Technology Severe acute respiratory syndrome coronavirus 2 SARSCoV2 is the causative agent of for coronavirus disease 2019 COVID19. COVID19 is characterized by fever, cough, difficulty breathing, loss of taste and smell, nausea, and sore throat. As of the fourth quarter 2020, COVID19 is responsible for over 1.17 million deaths worldwide.
As the pandemic continues to surge, the importance of a safe, affordable, and efficacious vaccine is of urgent importance. The present technology utilizes the well characterized vesicular stomatitis virus VSV encoding the Ebola virus VSVEBOV to express additionally a codon-optimized SARS
CoV2 spike protein. A single intranasal or intramuscular administration of the vaccine showed protective efficacy against COVID19 in hamsters after 4
weeks. A single intramuscular injection showed protective efficacy against COVID19 pneumonia in rhesus macaques within 10 days. The vaccine is inexpensive to replicate, elicits a high antigen-specific antibody titer within
E:FRFM04FEN1.SGM
04FEN1
